News

Berlin, 9 September 2026

The Federal Joint Committee (GBA) is giving itself a new visual identity. The logo is being revised as well: the previous “G-BA” becomes the word mark …

For the active substance onasemnogene abeparvovec (Itvisma®) for the treatment of 5q spinal muscular atrophy (SMA) in patients aged 2 years and older with a biallelic mutation in the survival …

The medicinal product is identified as “bi-layer engineered skin composed of autologous keratinocytes and allogeneic fibroblasts embedded in an allogeneic plasma matrix”. It is indicated for the treatment of partial …

After 1.5 years of the EU-HTA (launched on 15 January 2025), the results so far are disappointing: Only 22 procedures have been initiated to date, of which 3 have been …

Berlin, 15 August 2026

In its first interim arbitration ruling, the arbitration board (Schiedsstelle) considers itself competent in cases where, after a routine practice data collection (anwendungsbegleitende Datenerhebung, AbD) has …

Berlin, 24 July 2026

Carsten Linnemann, former General-Secretary of the CDU, is taking over the responsibility of Federal Minister of Health from Nina Warken (CDU) – who is the new …

On Friday, 10 July 2026, in the last session before the summer break, the Bundestag and the Bundesrat passed the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-Beitragssatzstabilisierungsgesetz, BStabG) with …

The two procedures relate to Pharma Mar's Zepzelca (lurbinectedin) and Amgen's Imdylltra (tarlatamab), both for the treatment of extensive-stage small cell lung cancer (ES-SCLC), for which randomised controlled trials had …

The Federal Joint Committee (G-BA) has decided today which impartial member will chair each of the currently ten subcommittees until the end of the current term in 2030:

• Dr. Sonja …

The two EU-HTA procedures for the active substances catequentinib and Tacquell have been closed. The central issue is Article 9 of Regulation (EU) 2021/2282.

Article 9 requires an EU-HTA dossier …

Prof. Josef Hecken today chaired a plenary session as impartial chair of the G-BA for the last time. Since 2012, and thus for almost the entire period since the introduction …

Berlin, 12 June 2026 – The Third Ordinance amending the Medicinal Products Pricing Ordinance (AMPreisV) has been in force since 12 June 2026. The ordinance implements the coalition agreement and, …

The Bundestag's Health Committee has agreed on the new impartial chairperson of the Federal Joint Committee (G-BA). Sonja Optendrenk (CDU) will thus take the helm of the highest self-governing body …

The European Commission has published the first joint clinical assessment (JCA) report under the Health Technology Assessment (HTA) Regulation, marking a major milestone in strengthening cooperation on the assessment of …

The prescribing restriction was made because of the only mild to moderate effectiveness, the strong differences in how well the drugs work from patient to patient, and the side effects …

The AMNOG-Monitor now has a fresh look. After rebuilding the platform from the ground up last year to handle additional data sources such as EU-HTA and arbitration rulings, we've also …

The new European health technology assessment (EU-HTA) has reached an important milestone: the first joint assessment – led by Ireland's National Centre for Pharmacoeconomics (NCPE) as assessor and IQWiG as …

The Federal Joint Committee (G-BA) has found no added benefit over the current standard of care for the second new drug to treat early-stage Alzheimer's disease either. The decision is …